CELG
Celgene Corporation

12,291
Loading...
Loading...
News
all
press releases
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmunes parent company, Sichuan Biokin Pharmaceutical Co., Ltd...
Business Wire·10h ago
News Placeholder
More News
News Placeholder
Primecap Management Co. CA Sells 850,330 Shares of Bristol Myers Squibb Company $BMY
Primecap Management Co. CA lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3.7% during the third quarter, according to its most recent filing with the...
MarketBeat·10h ago
News Placeholder
Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by Royal Bank Of Canada
Royal Bank Of Canada raised shares of Bristol Myers Squibb to a "hold" rating in a research report on Tuesday...
MarketBeat·10h ago
News Placeholder
Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market
CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized cancer centers, with price tags of up to $400,000 per treatment.For the...
TheStreet.com·1d ago
News Placeholder
NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options
NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options PR Newswire NEW YORK, Feb. 25, 2026 NYSE issues...
PR Newswire·1d ago
News Placeholder
Dana Investment Advisors Inc. Sells 54,542 Shares of Bristol Myers Squibb Company $BMY
Dana Investment Advisors Inc. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 37.6% in the third quarter, according to the company in its most recent disclosure with...
MarketBeat·2d ago
News Placeholder
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity PR Newswire NEW YORK, Feb. 24, 2026...
PR Newswire·2d ago
News Placeholder
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. The company will take part in a...
Business Wire·3d ago
News Placeholder
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha ()-Thalassemia
Bristol Myers Squibb (NYSE: BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl (luspatercept-aamt) versus placebo...
Business Wire·3d ago
News Placeholder
AMG National Trust Bank Reduces Position in Bristol Myers Squibb Company $BMY
AMG National Trust Bank trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 86.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·4d ago
<
1
2
...
>

Latest CELG News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.